Alphamab OncologyHKEX: 9966

2026 Interim report

· Issued by Alphamab Oncology via HKEXnews

Filed with HKEX · Stock code 9966 · · 83 pages · English

Summary by 6ix AI

The report includes a comprehensive overview of the company's product pipeline, including innovative therapies and their development stages. It also discusses the company's research and development capabilities and recent achievements in clinical trials and regulatory approvals. Financial highlights and condensed consolidated financial statements are presented to provide insights into the company's financial health.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Alphamab Oncology on 6ix

Earlier from Alphamab Oncology

Later from Alphamab Oncology

All Alphamab Oncology news releases